Is TNXP or TRVI more undervalued in 2026?

CirclFi compares Tonix Pharmaceuticals Holding C (TNXP) and Trevi Therapeutics, Inc. (TRVI) using 13 institutional-grade valuation models. TNXP has a Quality of Company score of 6.1/10 while TRVI scores 4.2/10.

Which is a better buy — TNXP or TRVI?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TNXP and TRVI valuations compare?

TNXP at $12.64 and TRVI at $14.45 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TNXP vs TRVI Valuation Comparison 2026 — Intrinsic Value Analysis

TNXP

Biotechnology

Tonix Pharmaceuticals Holding C

Quality

6.1

out of 10

Value Trap

LOW

Price

$12.64

Last close

Models

12/13

Active

TRVI

Biotechnology

Trevi Therapeutics, Inc.

Quality

4.2

out of 10

Value Trap

LOW

Price

$14.45

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	TNXP Fair Value	TNXP Upside	TRVI Fair Value	TRVI Upside
Bayesian DCF	Intrinsic	$9.52	-24.7%	$4.39	-69.7%
Earnings Power Value	Intrinsic	$20.65	+51.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$3.17	-74.9%	$0.40	-97.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TNXP vs TRVI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TNXP vs TRVI — Which Stock Is More Undervalued?

TNXP scores higher with a 6.1/10 quality rating vs TRVI's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Tonix Pharmaceuticals Holding C (TNXP) and Trevi Therapeutics, Inc. (TRVI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TNXP currently trades at $12.64 with a QOC of 6.1/10, while TRVI trades at $14.45 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).